PPARGC1A and diabetes mellitus: The mechanism underlying the positive effect of SGLT2 inhibitors on diabetes-related renal impairment has recently been found to be that they regulate the hyperglycemia-induced PGC-1α expression in various cells [47–49] (see Figure 2).